Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuromuscular and neurological diseases. The company commercializes prescription drugs including Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for epilepsy, and Agamree for Duchenne muscular dystrophy. Main revenue drivers consist of commercial drug sales of Firdapse, Fycompa, and Agamree to specialty pharmacies and healthcare distributors. Catalyst Pharmaceuticals serves neuromuscular specialists, pediatric neurologists, rare disease centers, and rare disease patients across the United States. The company holds a prominent market position as a specialized biopharmaceutical provider for ultra-rare neuromuscular disorders. Headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Catalyst Pharmaceuticals.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Catalyst Pharmaceuticals
- Simplicity Småbolag Global — Simplicity · 0.75 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.41 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.02 % (full portfolio disclosed, December 2025)